Therefore, the beneficial effect of SGLT2 inhibitors on the renal hemodynamics of these T2D patients with RAS blockade is most likely due to enhancement of post-glomerular vasodilatation in patients with T2D, as illustrated in Fig. 8b. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.